July 14, 2026 | Most ADCs today lean on the same Topo-1 payloads—and resistance is catching up. Jack Elands, Ph.D., founder and CEO of Adcytherix, speaks with host Rakesh Dixit, Ph.D. about what “next-generation ADCs” should mean if we care about patients, not just pipeline counts. Their conversation gets specific about where differentiation comes from: novel payloads with new mechanisms of action, better therapeutic index choices, and smarter design decisions that reduce the toxicities that make patients quit therapy early. They also pressure-test the hype around bispecific ADCs and dual-payload ADCs. 

Links from this episode:  

Adcytherix 

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Cambridge Healthtech Institute. Innehållet i podden är skapat av Cambridge Healthtech Institute och inte av, eller tillsammans med, Poddtoppen.